• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗肿瘤咪唑并四嗪类化合物——十六。3-取代咪唑并四嗪酮的大分子烷基化作用

Antitumour imidazotetrazines--XVI. Macromolecular alkylation by 3-substituted imidazotetrazinones.

作者信息

Bull V L, Tisdale M J

机构信息

Pharmaceutical Sciences Institute, Aston University, Birmingham, U.K.

出版信息

Biochem Pharmacol. 1987 Oct 1;36(19):3215-20. doi: 10.1016/0006-2952(87)90636-8.

DOI:10.1016/0006-2952(87)90636-8
PMID:2444229
Abstract

The extent of macromolecular alkylation by three imidazotetrazinones, 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4-(3H )-one (mitozolomide) and the 3-methyl CCRG 81045) and 3-ethyl (CCRG 82019) analogues has been studied both in intact cells and with isolated DNA, RNA and protein. Towards isolated DNA and RNA CCRG 81045 was about twice as reactive as mitozolomide and 5-10-fold more reactive than CCRG 82019. Two cell lines were chosen to study macromolecular alkylation, GM892A and Raji, the latter being 10-20-fold less sensitive to mitozolomide and CCRG 81045 than the former, but only one-and-a-half-fold less sensitive to CCRG 82019. Drug uptake into both cell lines was shown to be by a rapid diffusion process with a cell medium distribution ratio not far from unity. For all three agents intracellular radioactivity became associated with macromolecules, and the level found at any time is a balance between the rate of alkylation and the rate of alkyl group removal by repair processes. Both CCRG 81045 and CCRG 82019 produced approximately the same level of alkyl groups bound to DNA, RNA and protein over a 24-hr period, whereas mitozolomide produced a greater extent of alkylation. All three agents left more alkyl groups bound to DNA and RNA in GM892A than in Raji cells, but there was no difference in the level of alkyl groups remaining bound to proteins. However, in GM892A cells the overall level of alkylation of DNA by CCRG 81045 exceeded that of CCRG 82019 only after 24 hr of drug incubation despite the twenty-fold difference in potency of these agents. These results suggest that specific base alkylations rather than total macromolecular alkylation may be more important in determining relative cytotoxicity.

摘要

研究了三种咪唑并四嗪酮,即8-氨基甲酰基-3-(2-氯乙基)咪唑并[5,1-d]-1,2,3,5-四嗪-4-(3H)-酮(米托唑胺)及其3-甲基(CCRG 81045)和3-乙基(CCRG 82019)类似物在完整细胞以及分离的DNA、RNA和蛋白质中的大分子烷基化程度。对于分离的DNA和RNA,CCRG 81045的反应活性约为米托唑胺的两倍,比CCRG 82019高5至10倍。选择了两种细胞系来研究大分子烷基化,即GM892A和Raji,后者对米托唑胺和CCRG 81045的敏感性比前者低10至20倍,但对CCRG 82019的敏感性仅低1.5倍。结果表明,两种细胞系对药物的摄取均通过快速扩散过程,细胞与培养基中的分布比例接近1。对于所有三种药物,细胞内放射性均与大分子结合,在任何时刻检测到的水平是烷基化速率与修复过程中烷基去除速率之间的平衡。在24小时内,CCRG 81045和CCRG 82019与DNA、RNA和蛋白质结合的烷基水平大致相同,而米托唑胺的烷基化程度更高。所有三种药物在GM892A细胞中与DNA和RNA结合的烷基比在Raji细胞中更多,但与蛋白质结合的烷基水平没有差异。然而,在GM892A细胞中,尽管CCRG 81045和CCRG 82019的效力相差20倍,但仅在药物孵育24小时后,CCRG 81045对DNA的总体烷基化水平才超过CCRG 82019。这些结果表明,在确定相对细胞毒性方面,特定碱基的烷基化而非总的大分子烷基化可能更为重要。

相似文献

1
Antitumour imidazotetrazines--XVI. Macromolecular alkylation by 3-substituted imidazotetrazinones.抗肿瘤咪唑并四嗪类化合物——十六。3-取代咪唑并四嗪酮的大分子烷基化作用
Biochem Pharmacol. 1987 Oct 1;36(19):3215-20. doi: 10.1016/0006-2952(87)90636-8.
2
Antitumour imidazotetrazines and gene expression.抗肿瘤咪唑并四嗪与基因表达
Acta Oncol. 1988;27(5):511-6. doi: 10.3109/02841868809093579.
3
Antitumor imidazotetrazines--XV. Role of guanine O6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones.抗肿瘤咪唑并四嗪类化合物——XV. 鸟嘌呤O6烷基化在咪唑并四嗪酮细胞毒性机制中的作用
Biochem Pharmacol. 1987 Feb 15;36(4):457-62. doi: 10.1016/0006-2952(87)90351-0.
4
Antitumour imidazotetrazines--IV. An investigation into the mechanism of antitumour activity of a novel and potent antitumour agent, mitozolomide (CCRG 81010, M & B 39565; NSC 353451).抗肿瘤咪唑并四嗪类——IV。新型强效抗肿瘤药物米托唑胺(CCRG 81010,M&B 39565;NSC 353451)抗肿瘤活性机制的研究。
Biochem Pharmacol. 1984 Jul 15;33(14):2185-92. doi: 10.1016/0006-2952(84)90652-x.
5
Antitumour imidazotetrazines-X. Effect of 8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4-(3H)-one (CCRG 81045; M & B 39831; NSC 362856) on DNA methylation during induction of haemoglobin synthesis in human leukaemia cell line K562.
Biochem Pharmacol. 1986 Jan 15;35(2):311-6. doi: 10.1016/0006-2952(86)90531-9.
6
Antitumour imidazotetrazines--VIII. Uptake and decomposition of a novel antitumour agent mitozolomide (CCRG 81010; M and B 39565; NSC 353451) in TLX5 mouse lymphoma in vitro.抗肿瘤咪唑并四嗪类——VIII. 新型抗肿瘤药物米托蒽醌(CCRG 81010;M和B 39565;NSC 353451)在TLX5小鼠淋巴瘤细胞中的体外摄取与分解
Biochem Pharmacol. 1985 Jan 15;34(2):217-21. doi: 10.1016/0006-2952(85)90127-3.
7
Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine.8-氨基甲酰基-3-甲基-咪唑并[5,1-d]-1,2,3,5-四嗪-4(3H)-酮(CCRG 81045;M&B 39831)是一种有望替代达卡巴嗪的新型药物,对小鼠的抗肿瘤活性及药代动力学研究
Cancer Res. 1987 Nov 15;47(22):5846-52.
8
Antitumour imidazotetrazines--XVIII. Modification of the level of 5-methylcytosine in DNA by 3-substituted imidazotetrazinones.抗肿瘤咪唑并四嗪类化合物——十八。3-取代咪唑并四嗪酮对DNA中5-甲基胞嘧啶水平的修饰。
Biochem Pharmacol. 1989 Apr 1;38(7):1097-101. doi: 10.1016/0006-2952(89)90254-2.
9
Antitumour imidazotetrazines--XXIV. Growth suppression by DNA from cells treated with imidazotetrazinones.抗肿瘤咪唑并四嗪类化合物——二十四。咪唑并四嗪酮处理的细胞的DNA对生长的抑制作用
Biochem Pharmacol. 1991 Feb 1;41(3):339-43. doi: 10.1016/0006-2952(91)90529-e.
10
Anti-tumour imidazotetrazines. Part XXI. Mitozolomide and temozolomide: probes for the major groove of DNA.抗肿瘤咪唑并四嗪类化合物。第二十一部分。米托唑胺和替莫唑胺:DNA大沟的探针
Anticancer Drug Des. 1990 Feb;5(1):63-8.

引用本文的文献

1
Revisiting Temozolomide's role in solid tumors: Old is gold?重新审视替莫唑胺在实体瘤中的作用:旧药是否依然出色?
J Cancer. 2024 Apr 22;15(11):3254-3271. doi: 10.7150/jca.94109. eCollection 2024.
2
Combined Therapy with Dacarbazine and Hyperthermia Induces Cytotoxicity in A375 and MNT-1 Melanoma Cells.达卡巴嗪联合热疗诱导 A375 和 MNT-1 黑色素瘤细胞细胞毒性。
Int J Mol Sci. 2022 Mar 25;23(7):3586. doi: 10.3390/ijms23073586.
3
Temozolomide and Other Alkylating Agents in Glioblastoma Therapy.替莫唑胺及其他烷化剂在胶质母细胞瘤治疗中的应用
Biomedicines. 2019 Sep 9;7(3):69. doi: 10.3390/biomedicines7030069.
4
Chemosensitized radiosurgery for recurrent brain metastases.化疗增敏放疗治疗复发性脑转移瘤。
J Neurooncol. 2012 Nov;110(2):265-70. doi: 10.1007/s11060-012-0965-6. Epub 2012 Aug 22.
5
Pharmacokinetics of temozolomide administered in combination with O6-benzylguanine in children and adolescents with refractory solid tumors.替莫唑胺与O6-苄基鸟嘌呤联合应用于难治性实体瘤儿童和青少年的药代动力学
Cancer Chemother Pharmacol. 2009 Dec;65(1):137-42. doi: 10.1007/s00280-009-1015-8. Epub 2009 May 9.
6
IFN-beta sensitizes neuroblastoma to the antitumor activity of temozolomide by modulating O6-methylguanine DNA methyltransferase expression.干扰素-β通过调节O6-甲基鸟嘌呤DNA甲基转移酶的表达,使神经母细胞瘤对替莫唑胺的抗肿瘤活性敏感。
Mol Cancer Ther. 2008 Dec;7(12):3852-8. doi: 10.1158/1535-7163.MCT-08-0806. Epub 2008 Dec 3.
7
Population pharmacokinetics of temozolomide in cancer patients.替莫唑胺在癌症患者中的群体药代动力学。
Pharm Res. 2000 Oct;17(10):1284-9. doi: 10.1023/a:1026403805756.
8
Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells.O6-烷基鸟嘌呤-DNA烷基转移酶的缺失与替莫唑胺和洛莫司汀在人肿瘤细胞中的毒性增强相关。
Br J Cancer. 1993 Jun;67(6):1299-302. doi: 10.1038/bjc.1993.241.
9
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).替莫唑胺的I期试验(CCRG 81045:M&B 39831:NSC 362856)。
Br J Cancer. 1992 Feb;65(2):287-91. doi: 10.1038/bjc.1992.57.